Phagenesis LtdⓇ Secures $42 Million in Funding to Revolutionize Dysphagia Treatment: Introducing the Phagenyx

Phagenesis Ltd.Ⓡ is excited to announce a significant funding milestone, having raised an impressive $42 million to further advance its mission of transforming dysphagia treatment. Dysphagia, or difficulty swallowing, is a multifaceted condition that impacts millions worldwide, often hindering their ability to enjoy meals and maintain a fulfilling life. With the introduction of the Phagenyx, an innovative device that employs Pharyngeal Electrical Stimulation (PES), Phagenesis is pioneering a new era in dysphagia care. The Phagenyx is a non-invasive, user-friendly solution that effectively stimulates pharyngeal nerves, proving instrumental in helping patients regain control over their swallowing function. The capital raised will be directed towards expanding clinical trials, enhancing product development, and increasing accessibility for patients across various healthcare settings. This funding will also enable Phagenesis to increase awareness and education among healthcare providers and patients alike about the benefits of the Phagenyx technology. The company remains steadfast in its commitment to evidence-based practices and safety standards, ensuring that each innovation not only meets but exceeds the expectations of the dysphagia community. "This funding round is a testament to the potential impact of our technology and our unwavering commitment to improving lives," shared a Phagenesis spokesperson. As Phagenesis embarks on this exciting journey, it invites stakeholders, investors, and advocates to join in its mission to reshape dysphagia care. Stay connected with Phagenesis to keep abreast of exciting developments, breakthroughs, and the remarkable ways in which Phagenyx is aiding patients on their path to recovery.